No Data
No Data
Small-Cap Stocks Are Having a Moment. Check Out the 10 Biggest Winners.
Chatter about the timing of the Federal Reserve's first interest-rate cuts has shifted all the market hype from Goliath to David.
C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
Express News | C4 Therapeutics To Present Preliminary Monotherapy Data From Ongoing Phase 1 Trial Of CFT1946 At ESMO Congress 2024
C4 Therapeutics to Present Preliminary Monotherapy Data From the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation
C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why
C4 Therapeutics, Inc. (CCCC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy).
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science